

References

I-171

1. Micromedex®Solutions Compendia. 2020. Ocrelizumab.
2. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Ocrelizumab. 2020.
3. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. *N Engl J Med*. 2017;209-20.
4. Ocrevus (Ocrelizumab) injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 05/2020.
5. Hayes, Inc. Health Technology Brief. Ocrelizumab (Ocrevus; Genentech Inc.) for Primary Progressive and Relapsing-Remitting Multiple Sclerosis. Landsdale, PA: Hayes, Inc.; October 5, 2017. Accessed January 4, 2019.
6. Gelfand J, Cree B, & Hauser S. Ocrelizumab and other CD20+ b-cell-depleting therapies in multiple sclerosis. *Neurotherapeutics*. 2017;14:835-841.
7. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
8. Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. *Acta Neurologica Scandinavica*. 2017;136(3):168-186.
9. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *The Lancet*. 2018. 17(2):162-173.
10. Daniels K, van der Nat PB, Frequin STFM, et al. Real-world results of ocrelizumab treatment for primary progressive multiple sclerosis. *Multiple Sclerosis International*. 2020:1-6.
11. Dirks P, Zingler V, Leemhuis J, et al. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol. *BMC Neurology*. 2020;20(1):1-9.